Article,
Upscaling and Risk Evaluation of the Synthesis of the 3,5-Diamino-1H-Pyrazole, Disperazol
Contributors
Jansen, Charlotte Uldahl
0000-0002-1168-8002
[1]
Grier, Katja Egeskov
0000-0002-9854-1440
[1]
Andersen, Jens Bo
0000-0003-1720-1581
[2]
Hultqvist, Louise Dahl
0000-0003-0256-892X
[2]
Nilsson, Martin
0000-0001-6251-9842
[2]
Moser, Claus Ernst
0000-0002-7664-8570
[2]
[3]
Tolker-Nielsen, Tim
0000-0002-9751-474X
[2]
Qvortrup, Katrine M
0000-0003-3828-2069
(Corresponding author)
[1]
Affiliations
- [1] Technical University of Denmark [NORA names: DTU Technical University of Denmark; University; Denmark; Europe, EU; Nordic; OECD];
- [2] University of Copenhagen [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
- [3] Rigshospitalet [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD]
Abstract
This paper presents the work performed to transition a lab-scale synthesis (1 g) to a large-scale (400 g) synthesis of the 3-5-diamino-1H-Pyrazole Disperazol, a new pharmaceutical for treatment of antibiotic-resistant Pseudomonas aeruginosa biofilm infections. The potentially hazardous diazotisation step in the lab-scale synthesis was transformed to a safe and easy-to-handle flow chemistry step. Additionally, the paper presents an OSHA-recommended safety assessment of active compound E, as performed by Fauske and Associates, LLC, Burr Ridge, IL, USA.
Keywords
Fauske,
IL,
LLC,
USA,
association,
biofilm infections,
burr,
chemistry step,
evaluation,
infection,
lab-scale synthesis,
large-scale,
pharmaceuticals,
ridge,
risk,
risk evaluation,
steps,
synthesis,
treatment,
upscaling
